The best indicator for Thermo Fisher Scientific (TMO)
We backtested 20 indicators across daily, weekly and hourly charts on real Thermo Fisher Scientific (TMO) history. Here's what actually worked — risk-adjusted, out-of-sample, with costs.
EMA 20/50 Cross
On the daily chart, this is the strongest risk-adjusted edge we found for Thermo Fisher Scientific (TMO) over ~46.2 years — trailing buy-and-hold by 4.5% CAGR.
The winner on each chart
Every indicator, ranked
Ranked by Sharpe (risk-adjusted return). Hypothetical, fees included.
| # | Indicator | TF | CAGR | Sharpe | Max DD | Win | Trades | vs B&H |
|---|---|---|---|---|---|---|---|---|
| 1 | EMA 20/50 Cross ✓ | Daily | 8.4% | 0.47 | -54.3% | 45.3% | 106 | -4.5% |
| 2 | EMA 50/200 Cross ✓ | Daily | 8.1% | 0.45 | -57.4% | 44.8% | 29 | -4.9% |
| 3 | SMA 50/200 Cross ✓ | Daily | 8.1% | 0.45 | -63.1% | 46.4% | 28 | -4.9% |
| 4 | MACD ✓ | Weekly | 7.8% | 0.45 | -55.0% | 51.1% | 94 | -5.1% |
| 5 | EMA 20/50 Cross ✓ | Weekly | 7.4% | 0.42 | -61.0% | 50.0% | 20 | -5.5% |
| 6 | Rate of Change ✓ | Weekly | 7.2% | 0.42 | -64.4% | 46.1% | 141 | -5.7% |
| 7 | RSI Trend (>50) ✓ | Weekly | 7.2% | 0.41 | -60.0% | 42.9% | 119 | -5.7% |
| 8 | Donchian Breakout ✓ | Weekly | 7.0% | 0.41 | -46.7% | 45.0% | 40 | -6.0% |
| 9 | Donchian Midline ✓ | Weekly | 7.1% | 0.41 | -60.3% | 45.7% | 129 | -5.8% |
| 10 | RSI Trend (>50) ✓ | Daily | 6.2% | 0.39 | -44.0% | 37.5% | 621 | -6.7% |
| 11 | EMA-10 Trend ✓ | Weekly | 5.7% | 0.36 | -54.5% | 46.7% | 227 | -7.2% |
| 12 | ADX / DMI ✓ | Weekly | 4.9% | 0.34 | -45.1% | 47.3% | 74 | -8.0% |
| 13 | Donchian Breakout ✓ | Daily | 4.1% | 0.31 | -52.3% | 45.5% | 198 | -8.9% |
| 14 | CCI ✓ | Weekly | 4.1% | 0.31 | -65.5% | 80.5% | 41 | -8.8% |
✓ = held up out-of-sample. Hypothetical, costs included. See methodology.
For Thermo Fisher Scientific (TMO), EMA 20/50 Cross on the daily timeframe gave the best balance of return and risk in our test. It still trailed buy-and-hold on raw return — but remember: this is a hypothetical backtest of a standard rule, not a recommendation. Markets change. See the methodology and disclaimer.
More stock
Get the weekly edge report
The best-performing indicator per asset, what changed this week, and the honest caveats — straight to your inbox.